From Answers to Follow-Through: Where Healthcare AI May Create Its Next Real Value
Updated: Sep 7
Over the past few years, discussions about AI in healthcare have often centered on one question: Can AI understand medicine well enough to help doctors and patients make better decisions? While this question remains important, I believe it is no longer the most intriguing one.
A recent initiative from the OpenAI Foundation and the Common Health Coalition introduces a different question: Once we know what should be done, can AI help ensure it actually happens? This distinction may seem subtle, but it signifies a much larger shift in our perspective on healthcare AI.
The initiative, called Breakthroughs to Follow-Through (B2F), addresses a persistent problem in healthcare: medical breakthroughs do not automatically translate into improved health outcomes. We may already have effective screening methods, know which tests should follow, and possess effective treatments. Yet, patients often find themselves lost between screening, diagnosis, referral, treatment, and follow-up.
For me, the significance of this initiative lies not in hepatitis C but in the concept of follow-through.
Healthcare Already Knows More Than It Delivers
One peculiar aspect of modern healthcare is that our ability to generate information has advanced much faster than our capacity to turn that information into sustained action. We can detect more abnormalities, produce sophisticated imaging, sequence genomes, and continuously measure glucose, heart rate, sleep, and activity. AI is making this information easier to interpret.
However, more information does not necessarily equate to better health. A person may receive a 60-page health screening report indicating a lung nodule, elevated glucose, fatty liver, reduced bone density, and cardiovascular risk markers. The real challenge arises after the report is delivered.
Which issue matters most? What should happen next? What can safely wait? Which specialist should the person consult? Does the consultation actually occur? Was the recommended test completed? What happens afterward? Who notices if the person drops out halfway through the process?
Healthcare systems excel at managing individual episodes of care but are often inconsistent in overseeing the spaces between those episodes. This is where a significant amount of healthcare value is lost.
The Next Healthcare AI Problem May Be Execution
The first generation of healthcare AI primarily focused on intelligence. Can a model interpret an image? Summarize a medical record? Retrieve clinical evidence? Answer a patient's question? Support diagnostic reasoning? These capabilities are crucial and will continue to improve. However, there is a structural limit to an AI system that stops after producing an answer. A recommendation holds limited value if no action follows.
This leads us to a different model of healthcare AI: Data → Understanding → Priority → Action → Follow-through → Outcome. The AI does not need to become the doctor; in many cases, it should not. Instead, AI can serve as a persistent coordination layer around the patient and the healthcare system.
AI can help structure fragmented information, identify what needs attention, assist users in understanding priorities, coordinate the next service, recognize when an expected action has not occurred, help patients prepare for their next encounter, maintain continuity across providers and time, and determine what actually happened after the recommendation. This role is very different from that of an AI chatbot; it is closer to a health orchestration layer.
From AI Intelligence to Healthcare Infrastructure
This distinction also alters my perspective on commercial value. For a long time, healthcare technology companies have competed for access to one vital asset: medical knowledge, clinical data, physicians, pharmacies, diagnostics, insurance relationships, or patient traffic. However, none of these assets alone governs the entire patient journey.
A hospital may provide excellent treatment but have limited visibility once the patient leaves. A screening provider may identify risks but not manage what comes next. A pharmaceutical company may have an effective therapy but still depend on diagnosis, treatment initiation, and adherence. An insurer may finance care but not control the patient experience across numerous providers. A large AI model may conceptually understand all these systems but still lack the ability to make the real-world process happen.
This creates a potentially significant new layer: healthcare orchestration. The strategic asset is no longer just data or algorithms; it becomes the combination of Pathway × Provider × Action × Outcome. In other words: for this type of person, with this type of problem, what pathway should be activated? Which service node is appropriate? Did the action happen? What was the result? Over time, that system can learn not just from what was recommended but from what actually worked.
Why This Matters Beyond the United States
The U.S. healthcare system has its own fragmentation problems, but this challenge is not uniquely American. In China, the issue often manifests differently. There is already substantial medical capacity, particularly in major cities. The health screening market is large and sophisticated. Extensive hospital networks exist, and there is rapid adoption of digital health tools, alongside enormous interest in medical AI.
However, healthcare journeys remain highly fragmented. A person may move between a physical examination center, a tertiary hospital, several specialists, an imaging center, a pharmacy, a rehabilitation provider, and a digital health platform without anyone truly owning the entire process. Each participant completes its individual task, leaving the patient to integrate the system.
This fragmentation is especially evident in preventive health. We often emphasize that early detection matters, but early detection is only valuable if it leads to appropriate action. A positive screening result that never reaches a confirmatory diagnosis is not prevention. A risk finding without follow-up is merely information. A discharge plan without rehabilitation or follow-up does not ensure continuity of care.
The real opportunity lies not simply in creating another digital health platform but in building infrastructure that helps move people from Finding → Decision → Service → Completion → Outcome.
Longevity as a Practical Concern
This question is particularly relevant to longevity and healthspan. Longevity is often discussed in terms of biomarkers, advanced diagnostics, biological age, genetics, supplements, or emerging interventions. While these areas are interesting, I believe the more fundamental challenge is less glamorous: can people consistently make and complete better health decisions over many years?
Most long-term health outcomes are not determined by one extraordinary intervention. They emerge from a sequence of decisions: whether to investigate an abnormal finding, manage metabolic risk, maintain muscle strength, improve sleep, complete rehabilitation, follow up on a cardiovascular risk marker, or return for the next screening.
This is one reason we have developed NEXA Longevity around the idea of Longevity-as-a-Choice: not longevity as a promise, and not longevity as a number, but longevity as a continuously evolving set of informed health decisions.
Our design principle is that AI should act as a guide rather than an authority, helping people navigate priorities, pathways, and choices while professional medical judgment remains where it belongs. This direction increasingly points toward a broader architecture: not only helping people choose but also ensuring those choices become completed actions.
The loop becomes: Choice → Navigation → Action → Follow-through → Learning → Next Choice.
What This Means for AI Companies
There are broader implications for AI companies. As foundation models become more capable, providing a good answer will increasingly become a baseline capability. The differentiation will shift elsewhere. The question will become: can the AI operate within a real workflow? Can it interact with real institutions? Can it handle permissions and responsibility boundaries? Can it coordinate humans and software? Can it recover when something fails? Can it recognize when professional intervention is required? Can it track whether the desired outcome occurred?
This suggests that the next generation of valuable AI companies may not simply own the smartest model. They may own the most effective workflow and execution layer surrounding the model. In healthcare, this means integrating intelligence with care pathways, service networks, human professionals, governance, and outcome measurement. The competitive advantage may ultimately be less about the model itself and more about workflow + network + trust + outcome data.
From the Information Economy to the Outcome Economy
I suspect this pattern will extend far beyond healthcare. The internet has dramatically reduced the cost of finding information. Digital platforms have lowered the cost of completing transactions. Generative AI is decreasing the cost of producing knowledge, analysis, and recommendations. The next step may involve reducing the cost of coordinating complex actions.
In that world, the unit of value changes. It will no longer be: how many answers did the system generate? How many times did the user open the app? Instead, it will focus on: what actually got done? A legal AI may not only explain a contract but also coordinate the process required to complete the legal task. A financial AI may not only provide analysis but continuously organize the actions required to execute a financial plan within appropriate controls. A healthcare AI may not simply explain a medical report but help ensure that the right next step actually happens.
This points toward what could become an outcome economy. Businesses will increasingly compete based on their ability to coordinate fragmented resources around a user's objectives. AI becomes not merely an intelligence layer but a coordination layer between people, institutions, and services.
The Direction We Are Watching at NEXA
At NEXA Longevity, this aspect of the B2F initiative interests me the most. We are not viewing B2F as something to replicate. Different health systems require different operating models, payment mechanisms, and governance structures. What matters is the underlying principle.
Healthcare does not end when the correct recommendation is generated. It continues when the right action is completed, and its result informs the next decision. This shift changes how we think about technology, health navigation, and the types of healthcare companies that may ultimately become valuable.
The next major healthcare AI company may not be the one that knows the most medicine. It may be the company that can most reliably connect people, knowledge, decisions, providers, actions, and outcomes. This is a much more challenging problem. It is also, increasingly, the problem worth solving.
From answers to action. From action to follow-through. From follow-through to better health outcomes. This is the direction we are watching—and building toward.
Comments